Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2006

View Archived Issues

Sustained anti-HCV activity seen with albumin interferon alfa-2b/ribavirin

GV-1001 may prolong survival in pancreatic cancer patients

Stable disease reported in phase I study of PHA-739358, patient recruitment continues

IKKbeta inhibition a potential means of treating rheumatoid arthritis

OROS-methylphenidate improves driving performance in teens with ADHD

Medarex and PacMab to develop antibody therapeutics for cancer

Ablynx and Wyeth collaborate to develop Nanobodies targeting TNF-alpha

4SC and University of Munster advance H5N1 program

Phase II study of Hemopure cleared to continue

Combretastatin A-4 imidazole analogues show potential for cancer therapy

Oxygent development update

Clearance for Schering AG to be integrated into the Bayer Group

Boehringer Ingelheim updates advanced pipeline, with focus on oncology

CGC-11047 studied in patients with AMD

OcuCure uses seed funding to advance compounds for AMD

DMD foundations fund research into membrane sealant

AzaSite Plus begins phase I safety study

Bioniche begins phase III trial of Urocidin for refractory bladder cancer

Cannasat Therapeutics signs contribution agreement for CAT-210

Provenge prolongs PSA doubling time in patients with early stage prostate cancer

Promising preclinical data for novel human mAb in IGF-1R-expressing tumors

Vertex reviews third quarter

Noxafil approved in E.U. for invasive fungal infections

Infuse Bone Graft recommended for approval in third indication

New anticancer agents patented

Novel antiinfective agents disclosed in recent patent literature

Novel compounds with potential for treatment of gastrointestinal disorders reported

CBP-501: Preliminary phase I results and pharmacokinetic data

Phase I and pharmacokinetic data on CX-3543, a first-in-class rRNA biogenesis inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...